文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

二价RSVpreF孕期接种预防日本婴儿RSV疾病的效力与安全性:关键随机3期MATISSE试验的亚组分析

Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
PubMed 文献 · Vaccine · 2024-06-08

该研究为全球3期随机双盲安慰剂对照MATISSE试验的日本参与者亚组分析,孕妇24-36周随机1:1接种RSVpreF或安慰剂。结果显示婴儿出生后180天内RSV-MA-LRTI效力87.6%,严重RSV-MA-LRTI效力75.1%,未发现安全性问题。

要点

  • 日本孕妇接种RSVpreF后,婴儿出生后180天内RSV-MA-LRTI疫苗效力为87.6%。
  • 严重RSV-MA-LRTI在180天内的疫苗效力为75.1%,置信区间宽。
  • 接种后1个月内不良事件率在RSVpreF组与安慰剂组相似,未发现安全性问题。

核心结论

  • 日本参与者的安全性和效力数据与MATISSE总体结果一致,支持孕期RSVpreF接种对婴儿严重MA-RSV-LRTI/MA-RSV-LRTI的效力,未发现安全性问题。

研究设计与样本

  • 全球3期随机双盲安慰剂对照MATISSE试验的日本参与者亚组分析,孕妇24-36周随机1:1接种RSVpreF或安慰剂。
  • 日本230名孕妇接种RSVpreF、232名接种安慰剂,其婴儿分别有218名和216名纳入分析。

主要发现

  • 婴儿出生后90天内RSV-MA-LRTI疫苗效力100.0%(95%CI 30.9-100.0;RSVpreF组0例,安慰剂组7例)。
  • 婴儿出生后180天内RSV-MA-LRTI疫苗效力87.6%(95%CI 7.2-99.7;RSVpreF组1例,安慰剂组8例)。
  • 婴儿出生后90天内严重RSV-MA-LRTI疫苗效力100.0%(95%CI -140.9-100.0;RSVpreF组0例,安慰剂组3例)。
  • 婴儿出生后180天内严重RSV-MA-LRTI疫苗效力75.1%(95%CI -151.5-99.5;RSVpreF组1例,安慰剂组4例)。
  • 接种/出生后1个月内不良事件率:RSVpreF组孕妇16.1%、婴儿48.6%,安慰剂组孕妇19.8%、婴儿50.5%;早产率RSVpreF组3.2%、安慰剂组6.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maternal vaccination with respiratory syncytial virus prefusion F vaccine (RSVpreF) is effective at preventing RSV-associated lower respiratory tract illness (LRTI) in newborns/infants. METHODS: This subgroup analysis from the global, phase 3, randomized, double-blind, placebo-controlled MATISSE (Maternal Immunization Study for Safety and Efficacy) trial evaluated participants enrolled in Japan. Pregnant women 24-36 weeks' gestation were randomized 1:1 to receive RSVpreF or placebo. Maternal safety endpoints included local reactions/systemic events within 7 days, adverse events (AEs) through 1 month, and serious AEs (SAEs) through 6 months after vaccination. In infants born to maternal participants, safety endpoints included specific birth outcomes, AEs through 1 month after birth, and SAEs and newly diagnosed chronic medical conditions through 12 or 24 months after birth. Vaccine efficacy in infants was assessed against RSV-positive, medically attended LRTI (RSV-MA-LRTI) and severe RSV-MA-LRTI through 180 days after birth. RESULTS: In Japan, 230 maternal participants received RSVpreF and 232 received placebo; 218 and 216 infants born to these mothers, respectively, were analyzed. Observed vaccine efficacy (95 % CIs) against infant RSV-MA-LRTI within 90 and 180 days after birth was 100.0 % (30.9, 100.0; RSVpreF, 0 cases; placebo, 7 cases) and 87.6 % (7.2, 99.7; RSVpreF, 1 case; placebo, 8 cases), respectively. Vaccine efficacy (95 % CIs) against severe RSV-MA-LRTI within 90 and 180 days was 100.0 % (-140.9, 100.0; RSVpreF, 0 cases; placebo, 3 cases) and 75.1 % (-151.5, 99.5; RSVpreF, 1 case; placebo, 4 cases), respectively. No safety concerns were identified. AE rates ≤1 month after vaccination/birth were similar in the RSVpreF (maternal, 16.1 %; infant, 48.6 %) and placebo (19.8 %; 50.5 %) groups. Preterm birth rates were also similar (RSVpreF, 3.2 %; placebo, 6.0 %). CONCLUSIONS: Safety and efficacy data in Japanese participants were consistent with overall MATISSE results, supporting the efficacy of maternal RSVpreF vaccination against severe MA-RSV-LRTI/MA-RSV-LRTI in infants, with no safety concerns. NCT04424316.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Otsuki T, Akada S, Anami A, et al. Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial. Vaccine. 2024. PMID: 38853036. doi:10.1016/j.vaccine.2024.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。